NIAID Celebrates Pivotal Step Toward Expanding HIV Prevention Choices for Women

Friday, July 24, 2020 Vaginal Ring for HIV Prevention Receives Positive Opinion from European Regulator The dapivirine ring, pictured here, is made of flexible silicone and continuously releases the anti-HIV drug dapivirine in the vagina. Credit: International Partnership for Microbicides Today the European Medicines Agency announced it has adopted a positive scientific opinion on the dapivirine vaginal ring for use by cisgender women ages 18 and older in developing countries to reduce their risk of HIV infection. This milestone marks an important step toward expanding the number of biomedical HIV prevention options available to women in sub-Saharan Africa, who are among those most affected by the HIV epidemic. NIAID thanks and congratulates everyone who led, conducted and participated in the research that led to the positive opinion. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107